Answers are grounded in this paper and cite their sources.
Review demonstrates how JAK-STAT signaling mediates immune and oncologic diseases, highlighting the clinical promise of targeted kinase inhibitors.
The Janus kinase (JAK)-signal transducer of activators of transcription (STAT) pathway is now recognized as an evolutionarily conserved signaling pathway employed by diverse cytokines, interferons, growth factors, and related molecules. This pathway provides an elegant and remarkably straightforward mechanism whereby extracellular factors control gene expression. It thus serves as a fundamental paradigm for how cells sense environmental cues and interpret these signals to regulate cell growth and differentiation. Genetic mutations and polymorphisms are functionally relevant to a variety of human diseases, especially cancer and immune-related conditions. The clinical relevance of the pathway has been confirmed by the emergence of a new class of therapeutics that targets JAKs.
No takes yet. Share an insight, caveat, or question.
O’Shea et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: